Articles

Cabotegravir maintains protective efficacy in the setting of bacterial STIs: A secondary analysis of HPTN 083

Clement, Meredith E.; Hanscom, Brett; Haines, Daniel; Bazan, Jose A.; Chotirosniramit, Nuntisa; Kofron, Ryan; Mannheimer, Sharon B.; Mayer, Kenneth H.; Secco Torres Silva, Mayara; Soto-Torres, Lydia; Rinehart, Alex R.; Rooney, James F.; Jennings, Andrea; Gomez-Feliciano, Kailazarid; McCauley, Marybeth; Grinsztejn, Beatriz; Landovitz, Raphael J.; HPTN 083 Study Team

In a large PrEP trial with high STI incidence, CAB-LA maintained robust protective efficacy relative to TDF/FTC in the setting of bacterial STIs.

Subjects

Files

  • thumbnail for CID 2024 CAB STI paper ciae572.pdf CID 2024 CAB STI paper ciae572.pdf application/pdf 459 KB

Also Published In

Title
Clinical Infectious Diseases
DOI
https://doi.org/10.1093/cid/ciae572

More About This Work

Academic Units
Medicine
Published Here
September 8, 2025